Tuesday, May 20, 2025
LBNN
  • Business
  • Markets
  • Politics
  • Crypto
  • Finance
  • Energy
  • Technology
  • Taxes
  • Creator Economy
  • Wealth Management
  • Documentaries
No Result
View All Result
LBNN

A game-changer in vaccine development? Examining their role in shaping the pandemic response

Simon Osuji by Simon Osuji
August 15, 2023
in Artificial Intelligence
0
A game-changer in vaccine development? Examining their role in shaping the pandemic response
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter


In a recent study published in The Lancet Infectious Diseases, scientists reviewed the history of using human challenge trials in developing vaccines.

The study explored vaccine development for 19 pathogens and the pitfalls and limitations associated with the process.

Study: Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy. Image Credit: solarseven/Shutterstock.comStudy: Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy. Image Credit: solarseven/Shutterstock.com

Background

The human challenge study consists of exposing volunteers to surrogate challenge agents or characterized pathogens under controlled conditions to understand the pathogenesis of the disease and evaluate the efficacy of therapies and vaccines.

Human challenge models have been used over the past several decades to understand and develop vaccines against more than 30 pathogens, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Unfortunately, vaccine development has a long history of intentional infection of humans with pathogens, starting with the deliberate and repeated exposure of a child to smallpox by Edward Jenner to demonstrate the efficacy of the vaccinia virus against smallpox.

Since then, human challenge studies have made significant strides in improving the ethical and regulatory aspects and accountability of medical research.

Recent assessments of the ethical frameworks related to human challenge studies have found that the acceptable risk associated with exposure to experimental interventions or pathogens for vaccine development must be balanced against the therapeutic agent’s social value or public health benefits.

About the study

In the present study, the scientists conducted a literature search to examine the link between human challenge trials for testing the efficacy of vaccines and the trajectory of vaccine development to distinguish between the facts and fiction concerning the role of human challenge trials in vaccine development.

The vaccine efficacy was first compared by pathogens across the human challenge and subsequent phase trials, and the findings were then further examined based on the contributions of human challenge trials in identifying correlates of protection and the selection of the vaccine.

The authors stated that the findings of this review could not be used to predict the success of using human challenge trials in future vaccine development. Thus, they aimed to assess the study-specific and overall factors related to the successful use of human challenge trials in vaccine development while identifying the intrinsic limitations to the process.

They examined human challenge trials to evaluate candidate vaccines against 19 pathogens, of which seven are in phase three or four trials.

Major findings

The review compared the efficacies of human challenge trials and field trials in vaccine development across various pathogens, including cholera, typhoid, malaria, shigella, influenza, smallpox, mpox, and respiratory syncytial virus.

The findings from these studies have indicated that on the whole, human challenge trials have played a significant role in the progression of vaccine development to subsequent phase trials, as well as in the selection of the adjuvant and immunization route and the designing of the vaccination regimen.

Surprisingly, the one exception has been in developing smallpox and mpox vaccines, where publications from phase three trials seem to prefer the data from animal challenge studies on efficacy and immunogenicity rather than human challenge trials.

The scientists also discussed the various human challenge studies that helped identify vaccine candidates that were not promising and down-select them to avoid further financial and resource expenditure.

These included candidate vaccines for malaria, typhoid, cholera, tuberculosis, Helicobacter pylori, enterotoxigenic Escherichia coli, Streptococcus pneumoniae, and shigella.

Additionally, the authors discussed the multiple aspects in which the fast-tracked production of the coronavirus disease 2019 (COVID-19) vaccine differed from the slow, traditional vaccine development process.

The rapid development of the COVID-19 vaccines was supported by substantial public investments in the form of funds and resources, as well as the presence of a large population of pathogen-naive individuals highly motivated to participate in the vaccine development process.

However, despite the significant difference in the circumstances motivating COVID-19 vaccine development compared to the traditional vaccine development process for other diseases, the advances in vaccine research during the COVID-19 pandemic have highlighted the importance of human challenge studies in accelerating vaccine development.

Furthermore, the impetus provided to vaccine development by the pandemic has also resulted in the development of novel tools, such as computer-generated and in-vitro models, and the use of immunity markers in testing the efficacy and immunogenicity of candidate vaccines.

Conclusions

Overall, the review provided a comprehensive assessment of the role of human challenge trials in developing vaccines overtime against a wide range of pathogens, and discussed the process’s various challenges and intrinsic limitations.

Furthermore, the study also compared the major factors that provided impetus to the rapid development of COVID-19 vaccines as compared to the traditional trajectory of vaccine development.

The findings suggested that the ethical and streamlined application of human challenge studies can be used to accelerate the development of vaccines against a wide range of diseases.

Journal reference:

  • Abo, Y., Jamrozik, E., McCarthy, J. S., Roestenberg, M., Steer, A. C., & Osowicki, J. (2023) Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy. The Lancet Infectious Diseases. doi: 10.1016/S14733099(23)002943. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00294-3/fulltext?rss=yes#%20



Source link

Related posts

Nvidia RTX 5060: Specs, Release Date, Pricing, Features

Nvidia RTX 5060: Specs, Release Date, Pricing, Features

May 20, 2025
How to Watch Google I/O 2025 and What to Expect

How to Watch Google I/O 2025 and What to Expect

May 20, 2025
Previous Post

When NBA Legend Dirk Nowitzki Visited In-Laws in Kenya

Next Post

Alex Collins cause of death: Former Seahawks, Ravens running back dead at 28

Next Post
Alex Collins cause of death: Former Seahawks, Ravens running back dead at 28

Alex Collins cause of death: Former Seahawks, Ravens running back dead at 28

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

Anduril, General Atomics win more USAF money to develop robot wingmen

Anduril, General Atomics win more USAF money to develop robot wingmen

1 year ago
Music for the Holidays: A Conversation with Sen. Champion

Music for the Holidays: A Conversation with Sen. Champion

1 year ago
Scottish Africa Business Association and Scottish Development International Join Forces to Unlock Global Opportunities for Scottish Companies

Scottish Africa Business Association and Scottish Development International Join Forces to Unlock Global Opportunities for Scottish Companies

1 week ago
Husband Offers Phor $20K Indecent Proposal To Cuckold Wife

Husband Offers Phor $20K Indecent Proposal To Cuckold Wife

2 years ago

POPULAR NEWS

  • Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    Ghana to build three oil refineries, five petrochemical plants in energy sector overhaul

    0 shares
    Share 0 Tweet 0
  • When Will SHIB Reach $1? Here’s What ChatGPT Says

    0 shares
    Share 0 Tweet 0
  • Matthew Slater, son of Jackson State great, happy to see HBCUs back at the forefront

    0 shares
    Share 0 Tweet 0
  • Dolly Varden Focuses on Adding Ounces the Remainder of 2023

    0 shares
    Share 0 Tweet 0
  • US Dollar Might Fall To 96-97 Range in March 2024

    0 shares
    Share 0 Tweet 0
  • Privacy Policy
  • Contact

© 2023 LBNN - All rights reserved.

No Result
View All Result
  • Home
  • Business
  • Politics
  • Markets
  • Crypto
  • Economics
    • Manufacturing
    • Real Estate
    • Infrastructure
  • Finance
  • Energy
  • Creator Economy
  • Wealth Management
  • Taxes
  • Telecoms
  • Military & Defense
  • Careers
  • Technology
  • Artificial Intelligence
  • Investigative journalism
  • Art & Culture
  • Documentaries
  • Quizzes
    • Enneagram quiz
  • Newsletters
    • LBNN Newsletter
    • Divergent Capitalist

© 2023 LBNN - All rights reserved.